市场调查报告书
商品编码
1291591
非处方药(OTC)市场:2023-2028年全球行业趋势、份额、规模、增长、机会和预测Over The Counter (OTC) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年,全球非处方药(OTC)市场规模达到1588亿美元。展望未来,IMARC集团预计,到2028年,市场规模将达到2317亿美元,在2023-2028年期间呈现6.24%的增长率(CAGR)。
非处方药(OTC),也被称为非处方药,可以在没有处方的情况下使用,也不需要寻求医疗专业人士的治疗。它们安全有效,有助于治疗疼痛、咳嗽和感冒、腹泻、便秘、痤疮和控制复发性偏头痛和过敏。目前,它们在全球各地的药店、便利店、超市和加油站都有销售。
越来越多的人利用非处方药来治疗小病,这是促进市场增长的关键因素之一。除此之外,OTC药物,如抗酸剂、组胺-2(H2)阻断剂和质子泵抑制剂(PPI),被用来缓解和预防烧心或消化不良。此外,由于冠状病毒疾病(COVID-19)的爆发,个人对自我护理的重要性的认识也在提高。这反过来又增加了营养补充剂的销售,加强了市场的增长。此外,主要参与者正在扩大他们的产品组合,以扩大他们的消费者基础和增加他们的地理分布。再加上监管机构越来越多地批准将处方药转换为非处方药,这对市场产生了积极的影响。除此以外,由于医疗费用的增加,目前选择非处方药而不是咨询医生的人越来越多。此外,自我治疗的做法可以帮助控制慢性疾病,减少缺勤,并节省稀缺的医疗资源,避免在小病中被耗尽。其他一些因素,如全球老年人口的增加,分销渠道的快速扩张,以及制药业的大幅增长,都在推动整体销售和盈利。
The global over the counter (OTC) drugs market size reached US$ 158.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 231.7 Billion by 2028, exhibiting a growth rate (CAGR) of 6.24% during 2023-2028.
Over the counter (OTC) drugs, also known as non-prescription drugs, can be used without a prescription or the need for seeking treatment by a healthcare professional. They are safe and effective and help cure pain, cough and cold, diarrhea, constipation, acne and manage recurring migraines and allergies. They are currently available in pharmacies, convenience stores, supermarkets and gas stations across the globe.
The increasing utilization of OTC drugs to treat minor ailments among individuals represents one of the key factors bolstering the market growth. Besides this, OTC medications, such as antacids, histamine-2 (H2) blockers, and proton pump inhibitors (PPIs), are used to relieve and prevent heartburn or acid indigestion. In addition, due to the coronavirus disease (COVID-19) outbreak, there is a rise in awareness among individuals about the importance of self-care. This, in turn, is increasing the sales of nutritional supplements and strengthening the market growth. Moreover, key players are expanding their product portfolio to widen their consumer base and increase their geographical presence. This, coupled with the increasing approvals from regulatory bodies for switching prescription drugs to OTC drugs, is positively influencing the market. Apart from this, there is currently an increase in the number of people opting for OTC drugs rather than consulting physicians on account of increasing healthcare costs. Furthermore, self-medication practices can assist in controlling chronic diseases, reducing absenteeism from work, and saving scarce medical resources from being exhausted during minor conditions. Some of the other factors, such as the rising geriatric population worldwide, rapid expansion of distribution channels, and significant growth in the pharmaceutical industry, are driving the overall sales and profitability.
IMARC Group provides an analysis of the key trends in each sub-segment of the global over the counter (OTC) drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product type, route of administration, dosage form and distribution channel.
Cough, Cold and Flu Products
Analgesics
Dermatology Products
Gastrointestinal Products
Vitamins, Minerals and Supplements (VMS)
Weight-loss/Dietary Products
Ophthalmic Products
Sleeping Aids
Others
Oral
Parenteral
Topical
Others
Tablets and Capsules
Liquids
Ointments
Others
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Alkem Laboratories Limited, Bayer AG, Daiichi Sankyo Company Limited, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Perrigo Company plc, Pfizer Inc., Piramal Enterprises Ltd., Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.
Key Questions Answered in This Report
1. What was the size of the global over the counter (OTC) drugs market in 2022?
2. What is the expected growth rate of the global over the counter (OTC) drugs market during 2023-2028?
3. What are the key factors driving the global over the counter (OTC) drugs market?
4. What has been the impact of COVID-19 on the global over the counter (OTC) drugs market?
5. What is the breakup of the global over the counter (OTC) drugs market based on the product type?
6. What is the breakup of the global over the counter (OTC) drugs market based on the route of administration?
7. What is the breakup of the global over the counter (OTC) drugs market based on the dosage form?
8. What is the breakup of the global over the counter (OTC) drugs market based on the distribution channel?
9. What are the key regions in the global over the counter (OTC) drugs market?
10. Who are the key players/companies in the global over the counter (OTC) drugs market?